Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERKLIN 2: domatinostat plus avelumab in advanced Merkel cell carcinoma after PD-(L)1 therapy progression
NL-OMON49071Phase 2Active, not recruiting
- Sponsor
- 4SC AG
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Domatinostat and avelumab in Merkel cell carcinoma (MCC) (2 cohorts), sponsored by 4SC AG. Primary endpoint: Antitumor efficacy. Started Oct 2021; status: active, not recruiting.
02
Drugs
Domatinostatavelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NL-OMON49071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49071.